EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome

Andrea M Haqq iD, Christine Poitou iD, Wendy K Chung iD, Elizabeth Forsythe iD, Rushika Conroy iD, Hélène Dollfus iD, Sonali Malhotra, Nicolas Touchot, Uzoma Okorie, Philip Beales, Karine Clément iD, Jesús Argente iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf079 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Andrea M Haqq und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, University of Alberta, Edmonton, AB, Canada T6G 2B7. Hauptthemen laut MEDLINE: Metabolic Syndrome, Bardet-Biedl Syndrome, alpha-MSH. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rhythm Pharmaceuticals, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Bardet-Biedl syndrome (BBS) is a rare genetic disease associated with disruptions in melanocortin-4 receptor pathway signaling that can contribute to increased risk for metabolic syndrome and obesity-related comorbidities.

Objective

Here, MetS-Z-BMI scores, a continuous measure based on body mass index (BMI), were calculated to determine metabolic syndrome severity and response to treatment with the melanocortin-4 receptor agonist setmelanotide in BBS.

Methods

All patients from a phase 3 study (NCT03746522) of setmelanotide with data required for the calculation of MetS-Z-BMI scores were included. Mean MetS-Z-BMI score was determined at baseline and Week 52; subgroup analyses were conducted by sex, age, genotype, and response to setmelanotide.

Results

MetS-Z-BMI scores were evaluable for 22 of 32 patients enrolled. Baseline mean (SD) MetS-Z-BMI score across patients was 1.1 (0.5); baseline mean (SD) odds ratios of future cardiovascular disease or type 2 diabetes were 3.1 (1.5) and 3.7 (1.7), respectively, for adults and 10.2 (4.7) and 2.8 (1.3), respectively, for pediatric patients. Overall, mean (SD) MetS-Z-BMI score at Week 52 was reduced by 0.34 (0.62). Mean (SD) MetS-Z-BMI scores significantly differed depending on achievement of predetermined weight-based thresholds of ≥10% weight loss (patients aged ≥18 years) or ≥0.3-point reduction in BMI Z score (patients aged <18 years) at Week 52 (achievers, −0.64 [0.54]; nonachievers, 0.08 [0.47]; P = .0043). No significant difference was observed with other subgroup comparisons.

Conclusion

MetS-Z-BMI score reductions were observed after 52 weeks of treatment, suggesting that setmelanotide may decrease metabolic syndrome severity and risk of future obesity-related comorbidities in those with BBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeBardet-Biedl Syndromealpha-MSHHumansMaleFemaleAdultMiddle AgedBody Mass IndexReceptor, Melanocortin, Type 4Young AdultRisk FactorsObesityAdolescentAged

Stichwörter der Autor:innen

cardiovascular diseasecomorbiditiesgenetics/genomicshypothalamusmetabolic syndrometype 2 diabetes

Substanzen

alpha-MSHsetmelanotideReceptor, Melanocortin, Type 4

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology, University of Alberta, Edmonton, AB, Canada T6G 2B7.
  • Nutrition Department, Reference Center of Rare Diseases PRADORT, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris 75013, France.
  • Sorbonne Université, Inserm, Nutrition and Obesities, Systemic Approaches NutriOmique Research Group, Paris 75013, France.
  • Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Clinical Genetics Department, Guys and St. Thomas' Hospitals, London; National Bardet-Biedl Syndrome Clinics, Great Ormond Street Hospital, London WC1N 3BH, UK.
  • Division of Weight Management, Division of Pediatric Endocrinology, Maine Medical Center, Portland, ME 04102, USA.

ORCID-Profile: Andrea M Haqq, Christine Poitou, Wendy K Chung, Elizabeth Forsythe, Rushika Conroy, Hélène Dollfus, Karine Clément, Jesús Argente

Förderung

  • Rhythm Pharmaceuticals, Inc

Zitieren

APA

Haqq, A. M., Poitou, C., Chung, W. K., Forsythe, E., Conroy, R., Dollfus, H., Malhotra, S., Touchot, N., Okorie, U., Beales, P., Clément, K., & Argente, J. (2025). Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf079

Vancouver

Haqq AM, Poitou C, Chung WK, Forsythe E, Conroy R, Dollfus H, et al. Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf079

BibTeX
@article{Haqq2025,
  author = {Haqq, Andrea M and Poitou, Christine and Chung, Wendy K and Forsythe, Elizabeth and Conroy, Rushika and Dollfus, Hélène and Malhotra, Sonali and Touchot, Nicolas and Okorie, Uzoma and Beales, Philip and Clément, Karine and Argente, Jesús},
  title = {Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf079}
}
Kostenlos starten →